ElyssaMed stems from a discovery made at the Gustave Roussy Institute during the study of the remission of a cancer patient who had rejected all forms of medical treatment.
Studying the immunological characteristics of this patient's tumor remission, Dr. Fathia Mami-Chouaib's INSERM team U1186 "integrative immunology and oncology tumor genetics" was able to understand and mimic the underlying mechanism of the remission.
This led to the development of ElyssaTech®: a revolutionary new approach in the fight against cancer.
Gustave Roussy is pioneering the demonstration of immunotheray's effectiveness in Europe, click on the logo to get more informations :
ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction.
The company plans to apply its first candidate drug to other cancers that express or over express CTPP.
These notably, include cancers classified as "orphan diseases", such as:
• Small Cell lung cancer,
• Medullary thyroid cancers,
• Neuroendocrine tumors.
This vaccine is based on the discovery by the founding team of the tumor antigen CTPP - Preprocalcitonin, a precursor of the hormone calcitonin (CT).
The team demonstrated that CTPP, which is expressed or over-expressed in several human lung tumor types, is capable of inducing a specific immune response in many lung cancer patients and constitutes a promising candidate for an anti-tumor immunotherapy approach.
The ultimate goal is to develop a personalized vaccine composed not only of CTPP antigen, but also of peptides from mutated antigens identified in the tumor of each patient which will be the heart of the ElyssaTech® platform.
This technology differs from all other competing immunotherapy approaches as its mode of action will allow its use in multi-resistant patients.
